苯扎贝特与阿西莫司治疗高脂血症的比较

Bezafibrate vs acipimox in treating hyperlipidemia

目的 :观察苯扎贝特降低血脂的疗效。方法 :治疗组 4 1例 (男性 2 5例 ,女性 16例 ;年龄 64±s 8a)给苯扎贝特 0 .2 g ,po ,tid× 4wk。对照组 35例(男性 14例 ,女性 2 1例 ;年龄 61± 7a)给阿西莫司0 .2 5g ,po ,tid× 4wk。结果 :苯扎贝特降低血胆固醇 (TC)和三酰甘油 (TG)的总有效率为 84 %和88%。阿西莫司降低血TC和TG的总有效率为77%和 67%。 2药且均有升高高密度脂蛋白胆固醇、载脂蛋白AI/载脂蛋白B10 0 的作用 ,苯扎贝特降低TG的水平高于阿西莫司 (P <0 .0 5)。结论 :苯扎贝特是一个安全、有效的降脂药物 。

AIM: To observe the antihyperlipidemia efficacy of bezafibrate. METHODS: Bezafibrate group (M 25, F 16; age 64±s 8 a) received bezafibrate 0.2 g, po, tid for 4 wk. Control group (M 14, F 21; age 61±7 a) received acipimox 0.25 g, po, tid for 4 wk. RESULTS: The clinical efficacy of bezafibrate for total cholesterol (TC) and triglycerides (TG) were 84% and 88%; acipimox were 77% and 67%; both drugs increased HDL-ch and Apo AI/Apo B 100 . Bezafibrate group decreased range of TG levels was senior to acipimox group (P<0.05). CONCLUSION: Bezafibrate is a safe and effective antihyperlipidemic drug, especially for the treatmet of hypertriglyceridemia.